Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2023 16:00 ET | Source: FibroGen, Inc.

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancersCollaboration expands FibroGen’s clinical pipeline with potential...
May 05, 2023 07:30 ET | Source: FibroGen, Inc.

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

SAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with...
May 01, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

Strengthens balance sheet with significant non-dilutive capital Aligned to support FibroGen operational plan Allows for the continued advancement of pamrevlumab, as well as our pre-clinical...
April 24, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen to Report First Quarter 2023 Financial Results

SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also...
April 03, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...
February 27, 2023 16:01 ET | Source: FibroGen, Inc.

FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results

Topline Data from Five Pivotal Phase 3 Trials in 2023Total Company Revenue $140.7 Million in 2022Continued Strong Roxadustat Volume Growth in China SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) --...
February 27, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen to Present at Cowen’s 43rd Annual Health Care Conference

SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at...
February 17, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close....
February 02, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen to Present at SVB Securities Global Biopharma Conference

SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB...
November 28, 2022 07:00 ET | Source: FibroGen, Inc.

FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of...